- Home
- SNES vs ZVSA Comparison
SNES vs ZVSA Comparison
Compare SNES & ZVSA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SNES
- ZVSA
- Stock Information
- Founded
- SNES 2004
- ZVSA 2014
- Country
- SNES United States
- ZVSA United States
- Employees
- SNES N/A
- ZVSA N/A
- Industry
- SNES Agricultural Chemicals
- ZVSA Biotechnology: Pharmaceutical Preparations
- Sector
- SNES Industrials
- ZVSA Health Care
- Exchange
- SNES Nasdaq
- ZVSA Nasdaq
- Market Cap
- SNES 6.7M
- ZVSA 3.0M
- IPO Year
- SNES 2016
- ZVSA N/A
- Fundamental
- Price
- SNES $5.06
- ZVSA $0.67
- Analyst Decision
- SNES Strong Buy
- ZVSA
- Analyst Count
- SNES 1
- ZVSA 0
- Target Price
- SNES $10.00
- ZVSA N/A
- AVG Volume (30 Days)
- SNES 244.6K
- ZVSA 1.4M
- Earning Date
- SNES 08-07-2025
- ZVSA 08-08-2025
- Dividend Yield
- SNES N/A
- ZVSA N/A
- EPS Growth
- SNES N/A
- ZVSA N/A
- EPS
- SNES N/A
- ZVSA N/A
- Revenue
- SNES $1,927,000.00
- ZVSA N/A
- Revenue This Year
- SNES $130.53
- ZVSA N/A
- Revenue Next Year
- SNES $80.00
- ZVSA N/A
- P/E Ratio
- SNES N/A
- ZVSA N/A
- Revenue Growth
- SNES 40.15
- ZVSA N/A
- 52 Week Low
- SNES $1.30
- ZVSA $0.47
- 52 Week High
- SNES $6.48
- ZVSA $6.30
- Technical
- Relative Strength Index (RSI)
- SNES 76.68
- ZVSA 53.43
- Support Level
- SNES $3.56
- ZVSA $0.61
- Resistance Level
- SNES $4.46
- ZVSA $0.73
- Average True Range (ATR)
- SNES 0.38
- ZVSA 0.07
- MACD
- SNES 0.10
- ZVSA 0.00
- Stochastic Oscillator
- SNES 97.61
- ZVSA 36.53
About SNES SenesTech Inc.
SenesTech Inc is a United States-based biotech platform and research company engaged in developing technology for managing animal pest populations through fertility control. The company provides its solutions to the animal market, commercial markets, and food markets. It currently has two product lines of fertility control products: ContraPest and Evolve.
About ZVSA ZyVersa Therapeutics Inc.
ZyVersa Therapeutics Inc is a clinical-stage biopharmaceutical company leveraging proprietary technologies to develop drugs for patients with chronic renal or inflammatory diseases with high unmet medical needs. The company has two proprietary globally licensed drug development platforms which are Cholesterol Efflux MediatorTM, VAR 200 (2-hydroxypropyl-beta-cyclodextrin) is an injectable drug in clinical development for the treatment of renal diseases. and IC 100 is a monoclonal antibody inflammasome ASC inhibitor in preclinical development for the treatment of inflammatory conditions.